ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,431.60
      -0.04%
      US Tech 100
      19,168.00
      0.52%
      Dow Jones
      38,589.16
      -0.15%
      Brent Oil
      82.275
      0.00%
      Bitcoin
      66,183.88
      0.27%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Inventiva (IVA)

      7. Inventiva (IVA) News

      IVA

      Inventiva (IVA)

      Inventiva
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:IVA
      DateTimeSourceHeadlineSymbolCompany
      05/30/20242:30AMGlobeNewswire Inc.Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024EU:IVAInventiva
      05/30/20242:30AMGlobeNewswire Inc.Combined General Meeting of June 20, 2024 - Availability of the preparatory documentsEU:IVAInventiva
      05/30/20242:30AMGlobeNewswire Inc.Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024EU:IVAInventiva
      05/30/20242:30AMGlobeNewswire Inc.Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoiresEU:IVAInventiva
      05/30/20242:30AMGlobeNewswire Inc.Combined General Meeting of June 20, 2024 - Availability of the preparatory documentsEU:IVAInventiva
      05/22/20244:00PMGlobeNewswire Inc.Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024EU:IVAInventiva
      05/21/20244:00PMGlobeNewswire Inc.Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateEU:IVAInventiva
      05/21/20244:00PMGlobeNewswire Inc.Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateEU:IVAInventiva
      05/21/20244:00PMGlobeNewswire Inc.Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activitésEU:IVAInventiva
      05/16/20244:00PMGlobeNewswire Inc.Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASHEU:IVAInventiva
      05/16/20244:00PMGlobeNewswire Inc.Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASHEU:IVAInventiva
      05/13/20242:30AMGlobeNewswire Inc.Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorEU:IVAInventiva
      05/13/20242:30AMGlobeNewswire Inc.Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorEU:IVAInventiva
      05/13/20242:30AMGlobeNewswire Inc.Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traitéEU:IVAInventiva
      04/03/20244:00PMGlobeNewswire Inc.Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FEU:IVAInventiva
      04/03/20244:00PMGlobeNewswire Inc.Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FEU:IVAInventiva
      04/03/20244:00PMGlobeNewswire Inc.Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)EU:IVAInventiva
      03/28/20243:00AMGlobeNewswire Inc.Inventiva announces the nomination of Andre Turenne as DirectorEU:IVAInventiva
      03/28/20243:00AMGlobeNewswire Inc.Inventiva announces the nomination of Andre Turenne as DirectorEU:IVAInventiva
      03/28/20243:00AMGlobeNewswire Inc.Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateurEU:IVAInventiva
      03/27/20244:00PMGlobeNewswire Inc.Inventiva reports its 2023 full-year resultsEU:IVAInventiva
      03/27/20244:00PMGlobeNewswire Inc.Inventiva publie ses résultats annuels 2023EU:IVAInventiva
      03/27/20244:00PMGlobeNewswire Inc.Inventiva reports its 2023 full-year resultsEU:IVAInventiva
      03/22/20244:00PMGlobeNewswire Inc.Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023EU:IVAInventiva
      03/22/20244:00PMGlobeNewswire Inc.Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsEU:IVAInventiva
      03/22/20244:00PMGlobeNewswire Inc.Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsEU:IVAInventiva
      03/18/20244:00PMGlobeNewswire Inc.Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2EU:IVAInventiva
      03/18/20244:00PMGlobeNewswire Inc.Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
      03/13/20244:00PMGlobeNewswire Inc.Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
      03/13/20244:00PMGlobeNewswire Inc.Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
       Showing the most relevant articles for your search:EU:IVA